文献速递静脉血栓栓塞

低剂量与治疗剂量DOAC在静脉血栓栓塞延长二级预防中的系统评价与Meta分析

Systematic Review and Meta-analysis on the Efficacy and Safety of Low Dose Anticoagulation Compared with Therapeutic Dose in the Extended Secondary Prophylaxis of Venous Thromboembolism.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2026-06-19

治疗剂量未降低复发VTE、肺栓塞或深静脉血栓风险,但显著增加大出血、临床相关非大出血及任何出血风险,提示低剂量更安全。

要点

  • 治疗剂量DOAC不降低VTE复发风险,但显著增加大出血风险(RR 1.66)。
  • 低剂量DOAC可作为VTE延长二级预防的更安全选择。
  • 癌症亚组与非癌症亚组间无显著差异,但非癌症研究中治疗剂量死亡风险有非显著升高趋势。

核心结论

  • 治疗剂量DOAC增加大出血和临床相关非大出血风险,且不降低VTE复发,低剂量是延长二级预防的更安全选择。

主要发现

  • 治疗剂量与低剂量相比,复发VTE风险无显著差异(RR 0.97,95%CI 0.70-1.34,p=0.86,中等证据质量)。

关键数值与推荐

  • 复发VTE:RR 0.97(95%CI 0.70-1.34,p=0.86,中等证据质量)。

临床怎么用

  • 在VTE延长二级预防中,可优先考虑低剂量DOAC以降低出血风险,同时不增加VTE复发。
  • 治疗剂量DOAC应权衡出血风险,尤其对于出血高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To review the relative efficacy and safety of low dose direct oral anticoagulants (DOACs) for extended secondary prevention of venous thromboembolism (VTE). DATA SOURCES: Medline and Scopus databases. REVIEW METHOD: The databases were searched on 25 October 2025 for randomised controlled trials (RCTs), comparing low dose with therapeutic dose anticoagulation with a DOAC. The study outcomes (including efficacy - recurrent VTE and safety - bleeding events) were expressed as risk ratios (RR) with 95% confidence intervals (CI). Certainty of evidence was assessed with the GRADE method. RESULTS: Five RCTs with 8 781 patients were included. Compared with the low dose, therapeutic dose did not reduce the risk of recurrent VTE (RR 0.97, 95% CI 0.70 - 1.34, p = .86, moderate certainty of evidence), pulmonary embolism (RR 1.02, 95% CI 0.66 - 1.60, p = .92, moderate certainty of evidence), or deep vein thrombosis (RR 0.86, 95% CI 0.53 - 1.39, p = .54, moderate certainty of evidence). Therapeutic anticoagulation significantly increased the risk of major bleeding (RR 1.66, 95% CI 1.18 - 2.34, p = .004, moderate certainty of evidence), clinically relevant non-major bleeding (RR 1.34, 95% CI 1.14 - 1.58, p < .001, high certainty of evidence), and any bleeding (RR 1.38, 95% CI 1.13 - 1.68, p = .002, moderate certainty of evidence). There were no subgroup differences between studies including only patients with cancer and those that did not, although a non-significant trend was observed (p = .10, I2 = 62.4%) for an increased risk of death (RR 1.51, 95% CI 1.03 - 2.19, p = .03, I2 = 48%) with the therapeutic dose in non-cancer studies. CONCLUSION: Therapeutic doses of DOACs increase the risk of major bleeding and clinically relevant non-major bleeding without decreasing VTE recurrence, making low doses a safer option for extended secondary VTE thromboprophylaxis.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kounoudi C, Serraou EA, Stathopoulou M, et al. Systematic Review and Meta-analysis on the Efficacy and Safety of Low Dose Anticoagulation Compared with Therapeutic Dose in the Extended Secondary Prophylaxis of Venous Thromboembolism. Eur J Vasc Endovasc Surg. 2026. PMID: 42320637. doi:10.1016/j.ejvs.2026.06.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。